Chengjian Zhao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Chengjian Zhao has a total of 161 co-authors. Here are the top co-authors by number of shared publications:
Chaoxin Xiao
State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, and Collaborative Innovation Center for Biotherapy
9 shared publicationsRuihan Zhou
State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, and Collaborative Innovation Center for Biotherapy
8 shared publications- Dan Cao
West China Hospital 1 Division of Abdominal Tumor, Department of Medical Oncology, Cancer Center and State Key Laboratory of Biological Therapy , Chengdu, China
7 shared publications Fujun Cao
State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, and Collaborative Innovation Center for Biotherapy
7 shared publicationsTongtong Xu
State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, and Collaborative Innovation Center for Biotherapy
7 shared publicationsXiaoying Li
Division of Abdominal Tumor, Department of Medical Oncology, Cancer Center and State Key Laboratory of Biological Therapy, West China Hospital, Sichuan University, Chengdu, China
7 shared publications
Latest Publications
- 16 November 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- p. OF1-OF15
Radiotherapy Combined with Serplulimab and Chemotherapy as First-line Treatment for Metastatic Pancreatic Adenocarcinoma: A Multicenter, Single-Arm, Phase II Trial
Purpose: The prognosis for metastatic pancreatic ductal adenocarcinoma (mPDAC) remains dismal. In this multicenter, single-arm, phase II study, we evaluated the combination of serplulimab, gemcitabine plus nab-paclitaxel (GnP), and radiotherapy (ICSBR regimen) as first-line treatment for patients with mPDAC (ChiCTR2300073237). Patients and Methods: Patients with mPDAC were enrolled in the first-line setting. The treatment regimen consisted of serplulimab and GnP administered in 21-day cycles, combined with stereotactic body radiotherapy (SBRT) directed at the primary or metastatic sites during cycle 2. Additionally, a comprehensive biomarker analysis was conducted. The primary endpoint was the 6-month progression-free survival (PFS) rate, with a predefined target of 60%. Results: Forty-six patients received at least one dose of treatment. The 6-month PFS rate was 78.3% [95% confidence interval (CI), 67.2%–91.1%]. The median PFS and overall survival (OS) were 8.5 months (95% CI, 7.3–12 months) and 14 months [95% CI, 12 months–not reached (NR)], respectively. The objective response rate (ORR) was 73.9% (95% CI, 58.9%–85.7%). The combination treatment was well tolerated, and no treatment-related deaths or unexpected safety signals were observed. Notably, patients with baseline circulating tumor DNA (ctDNA) negativity achieved a better survival. Moreover, tumor microenvironment (TME) analysis revealed that baseline fibroblast activation protein (FAP)–positive cancer-associated fibroblast (CAF) and T-cell proportions in tumor tissue correlated with clinical outcomes, with distinct spatial distribution and interaction tendencies observed among patients with different responses. Conclusions: Overall, the ICSBR regimen demonstrated a promising survival benefit as first-line treatment for mPDAC. Furthermore, ctDNA status and TME analysis highlighted potential markers for guiding precision treatment.
- 16 November 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- p. OF1-OF15
Radiotherapy Combined with Serplulimab and Chemotherapy as First-line Treatment for Metastatic Pancreatic Adenocarcinoma: A Multicenter, Single-Arm, Phase II Trial
Purpose: The prognosis for metastatic pancreatic ductal adenocarcinoma (mPDAC) remains dismal. In this multicenter, single-arm, phase II study, we evaluated the combination of serplulimab, gemcitabine plus nab-paclitaxel (GnP), and radiotherapy (ICSBR regimen) as first-line treatment for patients with mPDAC (ChiCTR2300073237). Patients and Methods: Patients with mPDAC were enrolled in the first-line setting. The treatment regimen consisted of serplulimab and GnP administered in 21-day cycles, combined with stereotactic body radiotherapy (SBRT) directed at the primary or metastatic sites during cycle 2. Additionally, a comprehensive biomarker analysis was conducted. The primary endpoint was the 6-month progression-free survival (PFS) rate, with a predefined target of 60%. Results: Forty-six patients received at least one dose of treatment. The 6-month PFS rate was 78.3% [95% confidence interval (CI), 67.2%–91.1%]. The median PFS and overall survival (OS) were 8.5 months (95% CI, 7.3–12 months) and 14 months [95% CI, 12 months–not reached (NR)], respectively. The objective response rate (ORR) was 73.9% (95% CI, 58.9%–85.7%). The combination treatment was well tolerated, and no treatment-related deaths or unexpected safety signals were observed. Notably, patients with baseline circulating tumor DNA (ctDNA) negativity achieved a better survival. Moreover, tumor microenvironment (TME) analysis revealed that baseline fibroblast activation protein (FAP)–positive cancer-associated fibroblast (CAF) and T-cell proportions in tumor tissue correlated with clinical outcomes, with distinct spatial distribution and interaction tendencies observed among patients with different responses. Conclusions: Overall, the ICSBR regimen demonstrated a promising survival benefit as first-line treatment for mPDAC. Furthermore, ctDNA status and TME analysis highlighted potential markers for guiding precision treatment.
- Open Access
- 24 September 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1891806
Gefitinib-based therapy in refractory hepatocellular carcinoma with EGFR overexpression: a spatial profiling-guided case report
Current systemic treatments for advanced hepatocellular carcinoma (HCC) such as antiangiogenic targeted therapies, immune checkpoint inhibitors (ICIs), and their combinations have shown benefit, but widespread drug resistance severely limits patient outcomes and underscores an urgent need for effective post-progression strategies. We herein present a case of a patient with advanced HCC who developed cutaneous, pulmonary, and lymphatic metastases following failure of multiple lines of tyrosine kinase inhibitors (TKIs) including donafenib and regorafenib, and lenvatinib plus anti-programmed death-1 (PD-1) monoclonal antibody (tislelizumab) alongside radiotherapy. Next-generation sequencing (NGS) of the primary liver surgical sample confirmed wild-type EGFR status without canonical driver mutations, whereas retrospective immunohistochemistry (IHC) and cyclic multiplexed tyramide signal amplification (CmTSA) of the cutaneous metastatic sample demonstrated EGFR protein overexpression. Subsequent spatial analysis demonstrated that EGFR-high tumor regions strongly correlated with hyper-proliferative Ki67+ tumor cells. Furthermore, this EGFR-high niche was spatially associated with an immunosuppressive microenvironment characterized by the infiltration of PD-L1+ myeloid cells, CD14+ monocytes, regulatory T cells (Tregs), and PD-L1+/IDO1+ tumor cells. Therefore, we formulated a spatial profiling-guided therapeutic hypothesis and added gefitinib to the prior regimen of lenvatinib plus tislelizumab concurrent with radiotherapy, achieving significant tumor regression despite subsequent intracranial progression. In conclusion, these findings suggest that spatial profiling offers valuable therapeutic insights, highlighting the potential benefit of an EGFR-targeted triplet strategy in refractory HCC with EGFR protein overexpression. While confounding effects from concurrent therapies cannot be excluded, this profiling-guided hypothesis warrants further prospective clinical and mechanistic validation.
- 24 September 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1891806
Open AccessGefitinib-based therapy in refractory hepatocellular carcinoma with EGFR overexpression: a spatial profiling-guided case report
Current systemic treatments for advanced hepatocellular carcinoma (HCC) such as antiangiogenic targeted therapies, immune checkpoint inhibitors (ICIs), and their combinations have shown benefit, but widespread drug resistance severely limits patient outcomes and underscores an urgent need for effective post-progression strategies. We herein present a case of a patient with advanced HCC who developed cutaneous, pulmonary, and lymphatic metastases following failure of multiple lines of tyrosine kinase inhibitors (TKIs) including donafenib and regorafenib, and lenvatinib plus anti-programmed death-1 (PD-1) monoclonal antibody (tislelizumab) alongside radiotherapy. Next-generation sequencing (NGS) of the primary liver surgical sample confirmed wild-type EGFR status without canonical driver mutations, whereas retrospective immunohistochemistry (IHC) and cyclic multiplexed tyramide signal amplification (CmTSA) of the cutaneous metastatic sample demonstrated EGFR protein overexpression. Subsequent spatial analysis demonstrated that EGFR-high tumor regions strongly correlated with hyper-proliferative Ki67+ tumor cells. Furthermore, this EGFR-high niche was spatially associated with an immunosuppressive microenvironment characterized by the infiltration of PD-L1+ myeloid cells, CD14+ monocytes, regulatory T cells (Tregs), and PD-L1+/IDO1+ tumor cells. Therefore, we formulated a spatial profiling-guided therapeutic hypothesis and added gefitinib to the prior regimen of lenvatinib plus tislelizumab concurrent with radiotherapy, achieving significant tumor regression despite subsequent intracranial progression. In conclusion, these findings suggest that spatial profiling offers valuable therapeutic insights, highlighting the potential benefit of an EGFR-targeted triplet strategy in refractory HCC with EGFR protein overexpression. While confounding effects from concurrent therapies cannot be excluded, this profiling-guided hypothesis warrants further prospective clinical and mechanistic validation.
- Open Access
- 7 May 2026
- Published by eLife Sciences Publications, Ltd in eLife
- Vol. 14
A novel 3D visualization method in mice identifies the periportal lamellar complex (PLC) as a key regulator of hepatic ductal and neuronal branching morphogenesis
The liver is a complex organ responsible for multiple functions, including metabolism, energy storage, detoxification, bile secretion, and immune regulation. Its highly organized vascular system plays a crucial role in maintaining functional zonation and tissue homeostasis. Within the liver, the hepatic artery, portal vein, hepatic vein, bile duct, and nerve networks intertwine to form an intricate three-dimensional architecture; however, traditional two-dimensional imaging fails to reveal their true spatial relationships, and current three-dimensional imaging methods remain insufficient to capture fine structural details. To achieve comprehensive visualization of these multi-ductal systems, we established a high-resolution three-dimensional imaging platform that combines multicolor perfusion of metallic compound nanoparticles (MCNPs) with an optimized tissue-clearing protocol (Liver-CUBIC), enabling simultaneous 3D reconstruction of the portal vein, hepatic artery, bile duct, and hepatic vein in mouse livers. Based on these data, we identified and defined a previously unrecognized structure located in the outer layer of the portal vein, termed the periportal lamellar complex (PLC). The PLC encircles the portal vein between the vascular endothelium and the perisinusoidal region, exhibits low-permeability barrier characteristics, and contains a distinctive population of CD34 + Sca-1 + endothelial cells. During liver fibrosis, the PLC extends from the portal vein toward the hepatic lobule, forming a structural scaffold that guides bile duct and nerve migration.
- 7 May 2026
- Published by eLife Sciences Publications, Ltd in eLife
- Vol. 14
Open AccessA novel 3D visualization method in mice identifies the periportal lamellar complex (PLC) as a key regulator of hepatic ductal and neuronal branching morphogenesis
The liver is a complex organ responsible for multiple functions, including metabolism, energy storage, detoxification, bile secretion, and immune regulation. Its highly organized vascular system plays a crucial role in maintaining functional zonation and tissue homeostasis. Within the liver, the hepatic artery, portal vein, hepatic vein, bile duct, and nerve networks intertwine to form an intricate three-dimensional architecture; however, traditional two-dimensional imaging fails to reveal their true spatial relationships, and current three-dimensional imaging methods remain insufficient to capture fine structural details. To achieve comprehensive visualization of these multi-ductal systems, we established a high-resolution three-dimensional imaging platform that combines multicolor perfusion of metallic compound nanoparticles (MCNPs) with an optimized tissue-clearing protocol (Liver-CUBIC), enabling simultaneous 3D reconstruction of the portal vein, hepatic artery, bile duct, and hepatic vein in mouse livers. Based on these data, we identified and defined a previously unrecognized structure located in the outer layer of the portal vein, termed the periportal lamellar complex (PLC). The PLC encircles the portal vein between the vascular endothelium and the perisinusoidal region, exhibits low-permeability barrier characteristics, and contains a distinctive population of CD34 + Sca-1 + endothelial cells. During liver fibrosis, the PLC extends from the portal vein toward the hepatic lobule, forming a structural scaffold that guides bile duct and nerve migration.
- Open Access
- 7 April 2026
- Published by eLife Sciences Publications, Ltd in eLife preprints
- Vol. 14
A Novel 3D Visualization Method in Mice Identifies the Periportal Lamellar Complex (PLC) as a Key Regulator of Hepatic Ductal and Neuronal Branching Morphogenesis
The liver is a complex organ responsible for multiple functions, including metabolism, energy storage, detoxification, bile secretion, and immune regulation. Its highly organized vascular system plays a crucial role in maintaining functional zonation and tissue homeostasis. Within the liver, the hepatic artery, portal vein, hepatic vein, bile duct, and nerve networks intertwine to form an intricate three-dimensional architecture; however, traditional two-dimensional imaging fails to reveal their true spatial relationships, and current three-dimensional imaging methods remain insufficient to capture fine structural details. To achieve comprehensive visualization of these multi-ductal systems, we established a high-resolution three-dimensional imaging platform that combines multicolor perfusion of metallic compound nanoparticles (MCNPs) with an optimized tissue-clearing protocol (Liver-CUBIC), enabling simultaneous 3D reconstruction of the portal vein, hepatic artery, bile duct, and hepatic vein in mouse livers. Based on these data, we identified and defined a previously unrecognized structure located in the outer layer of the portal vein, termed the Periportal Lamellar Complex (PLC). The PLC encircles the portal vein between the vascular endothelium and the perisinusoidal region, exhibits low-permeability barrier characteristics, and contains a distinctive population of CD34⁺Sca-1⁺ endothelial cells. During liver fibrosis, the PLC extends from the portal vein toward the hepatic lobule, forming a structural scaffold that guides bile duct and nerve migration.
- 7 April 2026
- Published by eLife Sciences Publications, Ltd in eLife preprints
- Vol. 14
Open AccessA Novel 3D Visualization Method in Mice Identifies the Periportal Lamellar Complex (PLC) as a Key Regulator of Hepatic Ductal and Neuronal Branching Morphogenesis
The liver is a complex organ responsible for multiple functions, including metabolism, energy storage, detoxification, bile secretion, and immune regulation. Its highly organized vascular system plays a crucial role in maintaining functional zonation and tissue homeostasis. Within the liver, the hepatic artery, portal vein, hepatic vein, bile duct, and nerve networks intertwine to form an intricate three-dimensional architecture; however, traditional two-dimensional imaging fails to reveal their true spatial relationships, and current three-dimensional imaging methods remain insufficient to capture fine structural details. To achieve comprehensive visualization of these multi-ductal systems, we established a high-resolution three-dimensional imaging platform that combines multicolor perfusion of metallic compound nanoparticles (MCNPs) with an optimized tissue-clearing protocol (Liver-CUBIC), enabling simultaneous 3D reconstruction of the portal vein, hepatic artery, bile duct, and hepatic vein in mouse livers. Based on these data, we identified and defined a previously unrecognized structure located in the outer layer of the portal vein, termed the Periportal Lamellar Complex (PLC). The PLC encircles the portal vein between the vascular endothelium and the perisinusoidal region, exhibits low-permeability barrier characteristics, and contains a distinctive population of CD34⁺Sca-1⁺ endothelial cells. During liver fibrosis, the PLC extends from the portal vein toward the hepatic lobule, forming a structural scaffold that guides bile duct and nerve migration.
- Open Access
- 10 March 2026
- Published by Springer Nature in Cell Discovery
- Vol. 12 (1) , 16
Integrative spatial profiling pipeline for determining TME architectures in archival clinical specimens using CmTSA superplex technology
The tumor microenvironment (TME) comprises diverse cellular components that spatially interact to form distinct functional niches (FNs). Profiling these TME spatial features has proven to be a critical approach for correlating tumor progression and therapeutic response. However, RNA stability limitations constrain the broad clinical implementation of spatial transcriptomics, while high background noise and low signal resolution compromise the accuracy of direct labeling-based spatial proteomic approaches in clinical specimens. To overcome these constraints in archival samples, we developed hybrid optochemical fluorescence depletion (HOC-FD) technology that integrates autofluorescence quenching with cyclic multiplex tyramide signal amplification (CmTSA) for formalin-fixed paraffin-embedded (FFPE) tissues. This unified platform enables the concurrent labeling of 30–60 biomarkers with ultrahigh signal-to-noise ratios while maintaining cost efficiency and compatibility with high-throughput processing of archival FFPE specimens. While superplex imaging captures multidimensional TME data, extracting spatial features from raw pixel-level outputs remains technically challenging. To resolve this problem, we implemented a computer vision pipeline beginning with deep learning-based cellular segmentation and phenotype classification under predefined biomarker annotation rules. Using single-cell spatial mapping of human colon and cervical cancer specimens, we systematically evaluated and selected radius-constrained neighborhood network (RNN) analysis to define functional niches, validating their accuracy and reliability in generating spatially coherent FNs with biological and prognostic relevance. In summary, the CmTSA platform combined with RNN-based spatial profiling provides an integrated framework for visualizing and quantifying multicellular functional states within architectures of the TME, potentially enhancing tumor immunology investigations and precision immunotherapies.
- 10 March 2026
- Published by Springer Nature in Cell Discovery
- Vol. 12 (1) , 16
Open AccessIntegrative spatial profiling pipeline for determining TME architectures in archival clinical specimens using CmTSA superplex technology
The tumor microenvironment (TME) comprises diverse cellular components that spatially interact to form distinct functional niches (FNs). Profiling these TME spatial features has proven to be a critical approach for correlating tumor progression and therapeutic response. However, RNA stability limitations constrain the broad clinical implementation of spatial transcriptomics, while high background noise and low signal resolution compromise the accuracy of direct labeling-based spatial proteomic approaches in clinical specimens. To overcome these constraints in archival samples, we developed hybrid optochemical fluorescence depletion (HOC-FD) technology that integrates autofluorescence quenching with cyclic multiplex tyramide signal amplification (CmTSA) for formalin-fixed paraffin-embedded (FFPE) tissues. This unified platform enables the concurrent labeling of 30–60 biomarkers with ultrahigh signal-to-noise ratios while maintaining cost efficiency and compatibility with high-throughput processing of archival FFPE specimens. While superplex imaging captures multidimensional TME data, extracting spatial features from raw pixel-level outputs remains technically challenging. To resolve this problem, we implemented a computer vision pipeline beginning with deep learning-based cellular segmentation and phenotype classification under predefined biomarker annotation rules. Using single-cell spatial mapping of human colon and cervical cancer specimens, we systematically evaluated and selected radius-constrained neighborhood network (RNN) analysis to define functional niches, validating their accuracy and reliability in generating spatially coherent FNs with biological and prognostic relevance. In summary, the CmTSA platform combined with RNN-based spatial profiling provides an integrated framework for visualizing and quantifying multicellular functional states within architectures of the TME, potentially enhancing tumor immunology investigations and precision immunotherapies.
- Open Access
Multi-Omics Reveals Activated Fibroblasts with Dual Functional Roles in Repair and Negative Barrier in the CD8 + T Cell Cytotoxic Niche for Lung Cancer Neoadjuvant Therapy
A major challenge in elucidating immune activation and tolerance is that single-omics technologies are inherently limited. Since single-cell transcriptomics lacks spatial information and spatial transcriptomics lacks resolution or depth, neither can adequately model the multidimensional tumor immune microenvironment (TiME) features. We present NICHE (Niche Integrated Cellular Heterogeneity Elucidator), an integrative multi-omics framework. By aligning physical cell-cell interactions with single-cell ligand-receptor (L-R) expression, NICHE leverages single-cell transcriptomics, spatial proteomics, and AI modeling to systematically decode the composition, spatial interactions, and communications within immune functional niches. To validate NICHE’s capabilities, we applied it to human tonsil tissue. The framework successfully identified key structural and functional units and deeply elucidated the cell-cell interactions and molecular crosstalk within them. Furthermore, these results were validated through orthogonal methods, including single-cell spatial transcriptomics and multiplexed immunofluorescence, which confirmed the accuracy and reproducibility of our analyses. In non-small cell lung cancer (NSCLC) patients undergoing neoadjuvant immunotherapy, CD8 + T cell cytotoxic niches mediate tumor clearance with variable outcomes, to define the cellular and molecular drivers behind this functional spectrum, we utilized NICHE to analyze the TiME from patients with complete versus partial pathological response, both pre- and post-treatment. We found that neoadjuvant immunotherapy may induce the activation of CXCL12 + , NECTIN2 + , POSTN + , and COL6A1 + fibroblasts through the activation of cytotoxic T cells. Paradoxically, these fibroblasts support tissue repair but also establish an immunosuppressive niche that protects residual tumor cells, ultimately attenuating treatment efficacy. Our work establishes a multidimensional framework for dissecting dynamic immune activity, with direct implications for understanding tumor immunology and identifying novel therapeutic targets.
Open AccessMulti-Omics Reveals Activated Fibroblasts with Dual Functional Roles in Repair and Negative Barrier in the CD8 + T Cell Cytotoxic Niche for Lung Cancer Neoadjuvant Therapy
A major challenge in elucidating immune activation and tolerance is that single-omics technologies are inherently limited. Since single-cell transcriptomics lacks spatial information and spatial transcriptomics lacks resolution or depth, neither can adequately model the multidimensional tumor immune microenvironment (TiME) features. We present NICHE (Niche Integrated Cellular Heterogeneity Elucidator), an integrative multi-omics framework. By aligning physical cell-cell interactions with single-cell ligand-receptor (L-R) expression, NICHE leverages single-cell transcriptomics, spatial proteomics, and AI modeling to systematically decode the composition, spatial interactions, and communications within immune functional niches. To validate NICHE’s capabilities, we applied it to human tonsil tissue. The framework successfully identified key structural and functional units and deeply elucidated the cell-cell interactions and molecular crosstalk within them. Furthermore, these results were validated through orthogonal methods, including single-cell spatial transcriptomics and multiplexed immunofluorescence, which confirmed the accuracy and reproducibility of our analyses. In non-small cell lung cancer (NSCLC) patients undergoing neoadjuvant immunotherapy, CD8 + T cell cytotoxic niches mediate tumor clearance with variable outcomes, to define the cellular and molecular drivers behind this functional spectrum, we utilized NICHE to analyze the TiME from patients with complete versus partial pathological response, both pre- and post-treatment. We found that neoadjuvant immunotherapy may induce the activation of CXCL12 + , NECTIN2 + , POSTN + , and COL6A1 + fibroblasts through the activation of cytotoxic T cells. Paradoxically, these fibroblasts support tissue repair but also establish an immunosuppressive niche that protects residual tumor cells, ultimately attenuating treatment efficacy. Our work establishes a multidimensional framework for dissecting dynamic immune activity, with direct implications for understanding tumor immunology and identifying novel therapeutic targets.
- Open Access
A Novel 3D Visualization Method in Mice Identifies the Periportal Lamellar Complex (PLC) as a Key Regulator of Hepatic Ductal and Neuronal Branching Morphogenesis
The liver is a complex organ responsible for multiple functions, including metabolism, energy storage, detoxification, bile secretion, and immune regulation. Its highly organized vascular system plays a crucial role in maintaining functional zonation and tissue homeostasis. Within the liver, the hepatic artery, portal vein, hepatic vein, bile duct, and nerve networks intertwine to form an intricate three-dimensional architecture; however, traditional two-dimensional imaging fails to reveal their true spatial relationships, and current three-dimensional imaging methods remain insufficient to capture fine structural details. To achieve comprehensive visualization of these multi-ductal systems, we established a high-resolution three-dimensional imaging platform that combines multicolor perfusion of metallic compound nanoparticles (MCNPs) with an optimized tissue-clearing protocol (Liver-CUBIC), enabling simultaneous 3D reconstruction of the portal vein, hepatic artery, bile duct, and hepatic vein in mouse livers. Based on these data, we identified and defined a previously unrecognized structure located in the outer layer of the portal vein, termed the Periportal Lamellar Complex (PLC). The PLC encircles the portal vein between the vascular endothelium and the perisinusoidal region, exhibits low-permeability barrier characteristics, and contains a distinctive population of CD34⁺Sca-1⁺ endothelial cells. During liver fibrosis, the PLC extends from the portal vein toward the hepatic lobule, forming a structural scaffold that guides bile duct and nerve migration.
Open AccessA Novel 3D Visualization Method in Mice Identifies the Periportal Lamellar Complex (PLC) as a Key Regulator of Hepatic Ductal and Neuronal Branching Morphogenesis
The liver is a complex organ responsible for multiple functions, including metabolism, energy storage, detoxification, bile secretion, and immune regulation. Its highly organized vascular system plays a crucial role in maintaining functional zonation and tissue homeostasis. Within the liver, the hepatic artery, portal vein, hepatic vein, bile duct, and nerve networks intertwine to form an intricate three-dimensional architecture; however, traditional two-dimensional imaging fails to reveal their true spatial relationships, and current three-dimensional imaging methods remain insufficient to capture fine structural details. To achieve comprehensive visualization of these multi-ductal systems, we established a high-resolution three-dimensional imaging platform that combines multicolor perfusion of metallic compound nanoparticles (MCNPs) with an optimized tissue-clearing protocol (Liver-CUBIC), enabling simultaneous 3D reconstruction of the portal vein, hepatic artery, bile duct, and hepatic vein in mouse livers. Based on these data, we identified and defined a previously unrecognized structure located in the outer layer of the portal vein, termed the Periportal Lamellar Complex (PLC). The PLC encircles the portal vein between the vascular endothelium and the perisinusoidal region, exhibits low-permeability barrier characteristics, and contains a distinctive population of CD34⁺Sca-1⁺ endothelial cells. During liver fibrosis, the PLC extends from the portal vein toward the hepatic lobule, forming a structural scaffold that guides bile duct and nerve migration.
- Open Access
- 20 August 2025
- Published by Springer Nature in Research Square
RETRACTED: Serplulimab combined with gemcitabine, nab-paclitaxel, and stereotactic body radiotherapy as first-line treatment for metastatic pancreatic adenocarcinoma: a multicentre, single-arm, phase II trial
The authors have requested that this preprint be removed from Research Square.
- 20 August 2025
- Published by Springer Nature in Research Square
Open AccessRETRACTED: Serplulimab combined with gemcitabine, nab-paclitaxel, and stereotactic body radiotherapy as first-line treatment for metastatic pancreatic adenocarcinoma: a multicentre, single-arm, phase II trial
The authors have requested that this preprint be removed from Research Square.
- Open Access
- 1 May 2025
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 16, 1547388
Case Report: Combined PD-1 and tyrosine kinase blockade stabilizes refractory pancreatic cancer guided by the spatial structure of tumor immune microenvironment
Pancreatic cancer is characterized by a poor prognosis and limited responsiveness to conventional therapies, presenting a substantial therapeutic challenge. Although chemotherapy remains the cornerstone of systemic treatment, options become scarce once frontline therapies fail. While targeted therapies and immunotherapies have emerged as potential alternatives, their efficacy in pancreatic cancer is not well established. As research advances, exploring the tumor immune microenvironment (TiME) of pancreatic cancer is crucial and holds significant potential for developing novel treatment strategies.We report a case of a pancreatic cancer patient who, after the failure of frontline and second-line treatments, was treated with a pioneering combination of targeted therapy and immunotherapy to modulate the unique TiME. The targeted agent, surufatinib, is a tyrosine kinase inhibitor (TKI) that targets vascular endothelial growth factor receptor (VEGFR) 1–3, fibroblast growth factor receptor 1 (FGFR1), and colony-stimulating factor 1 receptor (CSF-1R). The immunotherapy agent, toripalimab, is an immune checkpoint inhibitor targeting programmed cell death protein 1 (PD-1). Remarkably, the patient benefitted from this regimen, exhibiting stable disease, improved clinical symptoms, and prolonged progression-free survival. This case highlights the potential of personalized therapy in treating pancreatic cancer, particularly in patients with distinctive features of the TiME that may predict favorable responses to immunotherapy. Personalized strategies that consider the spatial structure and composition of the TiME may offer a promising avenue for achieving long-term progression-free survival in patients with pancreatic cancer.
- 1 May 2025
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 16, 1547388
Open AccessCase Report: Combined PD-1 and tyrosine kinase blockade stabilizes refractory pancreatic cancer guided by the spatial structure of tumor immune microenvironment
Pancreatic cancer is characterized by a poor prognosis and limited responsiveness to conventional therapies, presenting a substantial therapeutic challenge. Although chemotherapy remains the cornerstone of systemic treatment, options become scarce once frontline therapies fail. While targeted therapies and immunotherapies have emerged as potential alternatives, their efficacy in pancreatic cancer is not well established. As research advances, exploring the tumor immune microenvironment (TiME) of pancreatic cancer is crucial and holds significant potential for developing novel treatment strategies.We report a case of a pancreatic cancer patient who, after the failure of frontline and second-line treatments, was treated with a pioneering combination of targeted therapy and immunotherapy to modulate the unique TiME. The targeted agent, surufatinib, is a tyrosine kinase inhibitor (TKI) that targets vascular endothelial growth factor receptor (VEGFR) 1–3, fibroblast growth factor receptor 1 (FGFR1), and colony-stimulating factor 1 receptor (CSF-1R). The immunotherapy agent, toripalimab, is an immune checkpoint inhibitor targeting programmed cell death protein 1 (PD-1). Remarkably, the patient benefitted from this regimen, exhibiting stable disease, improved clinical symptoms, and prolonged progression-free survival. This case highlights the potential of personalized therapy in treating pancreatic cancer, particularly in patients with distinctive features of the TiME that may predict favorable responses to immunotherapy. Personalized strategies that consider the spatial structure and composition of the TiME may offer a promising avenue for achieving long-term progression-free survival in patients with pancreatic cancer.
- Open Access
- 1 January 2025
- Published by Ivyspring International Publisher in Theranostics
- Vol. 15 (1) , 258-276
Inhibiting autophagy selectively prunes dysfunctional tumor vessels and optimizes the tumor immune microenvironment
Dysfunctional tumor vasculature, hypoxia, and an immunosuppressive microenvironment are significant barriers to effective cancer therapy. Autophagy, which is critical for maintaining cellular homeostasis and apoptosis resistance, is primarily triggered by hypoxia and nutrient deprivation, conditions prevalent in dysfunctional tumor vessels due to poor circulation. However, the role of autophagy in dysfunctional tumor endothelial cells and its impact on treatment and the tumor microenvironment (TME) remain poorly understood.
- 1 January 2025
- Published by Ivyspring International Publisher in Theranostics
- Vol. 15 (1) , 258-276
Open AccessInhibiting autophagy selectively prunes dysfunctional tumor vessels and optimizes the tumor immune microenvironment
Dysfunctional tumor vasculature, hypoxia, and an immunosuppressive microenvironment are significant barriers to effective cancer therapy. Autophagy, which is critical for maintaining cellular homeostasis and apoptosis resistance, is primarily triggered by hypoxia and nutrient deprivation, conditions prevalent in dysfunctional tumor vessels due to poor circulation. However, the role of autophagy in dysfunctional tumor endothelial cells and its impact on treatment and the tumor microenvironment (TME) remain poorly understood.